Update on immunopathogenesis and immunotherapy in multiple sclerosis

被引：24

作者：

Selter, Rebecca C. ^{[1
]}

Hemmer, Bernhard ^{[1
,2
,3
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, Ismaninger Str 22, D-81675 Munich, Germany

[2] Munich Cluster Syst Neurol, Munich, Germany

[3] Competence Network Multiple Sklerosis, Munich, Germany

来源：

IMMUNOTARGETS AND THERAPY | 2013年 / 2卷

关键词：

multiple sclerosis; immunopathogenesis; disease-modifying therapy;

D O I：

10.2147/ITT.S31813

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. Both genetic and environmental factors are believed to contribute to the pathogenesis of the disease. Histopathological findings suggest that multiple sclerosis is an immune-mediated disease, involving both the cellular and humoral immune systems. Within the last 20 years, several disease-modifying therapies for the treatment of multiple sclerosis were established. Moreover, promising new substances are currently being tested in clinical trials and will likely broaden the therapeutic opportunities available within the upcoming years.

引用

页码：21 / 30

页数：10

共 91 条

[21]

Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs

[22] Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis [J].

Comi, Giancarlo ;

Jeffery, Douglas ;

Kappos, Ludwig ;

Montalban, Xavier ;

Boyko, Alexey ;

Rocca, Maria A. ;

Filippi, Massimo .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (11) :1000-1009

[23] Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study [J].

Connick, Peter ;

Kolappan, Madhan ;

Crawley, Charles ;

Webber, Daniel J. ;

Patani, Rickie ;

Michell, Andrew W. ;

Du, Ming-Qing ;

Luan, Shi-Lu ;

Altmann, Daniel R. ;

Thompson, Alan J. ;

Compston, Alastair ;

Scott, Michael A. ;

Miller, David H. ;

Chandran, Siddharthan .

LANCET NEUROLOGY, 2012, 11 (02) :150-156

[24] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[25]

European Medicines Agency, EUR MED AG GIV NEW A

[26] Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation [J].

Fagius, J. ;

Lundgren, J. ;

Oberg, G. .

MULTIPLE SCLEROSIS, 2009, 15 (02) :229-237

[27] Axonal damage in acute multiple sclerosis lesions [J].

Ferguson, B ;

Matyszak, MK ;

Esiri, MM ;

Perry, VH .

BRAIN, 1997, 120 :393-399

[28] Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis [J].

Fox, Robert J. ;

Miller, David H. ;

Phillips, J. Theodore ;

Hutchinson, Michael ;

Havrdova, Eva ;

Kita, Mariko ;

Yang, Minhua ;

Raghupathi, Kartik ;

Novas, Mark ;

Sweetser, Marianne T. ;

Viglietta, Vissia ;

Dawson, Katherine T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (12) :1087-1097

[29] AMINO-ACID HOMOLOGY BETWEEN THE ENCEPHALITOGENIC SITE OF MYELIN BASIC-PROTEIN AND VIRUS - MECHANISM FOR AUTOIMMUNITY [J].

FUJINAMI, RS ;

OLDSTONE, MBA .

SCIENCE, 1985, 230 (4729) :1043-1045

[30] The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis - Identification and characterization of the primary demyelinating lesion [J].

Gay, FW ;

Drye, TJ ;

Dick, GWA ;

Esiri, MM .

BRAIN, 1997, 120 :1461-1483

← 1 2 3 4 5 6 7 8 9 10 →